Kura Oncology (KURA) TD Cowen 46th Annual Health Care Conference summary

Company overview and strategic priorities

• 2026 is highlighted as a pivotal year, with a focus on driving quarter-over-quarter growth for Komzifti and establishing market leadership in NPM1-mutated AML.

• Two Kura-sponsored phase III trials are underway in intensive and non-intensive frontline AML, including combinations with marketed FLT3 inhibitors.

• Expansion into solid tumors is ongoing, with early dose escalation studies in GIST and multiple clinical data sets expected from darlifarnib combinations in 2024.

• The company maintains a strong cash position, financed through top-line results in frontline AML, and is exploring creative approaches in diabetes and cardiometabolic disease.

• No immediate plans for major external asset acquisitions, but ongoing clinical collaborations and portfolio expansion are anticipated.

Komzifti commercial launch and market feedback

• Komzifti launched 12 weeks ago for relapsed/refractory NPM1-mutated AML, showing strong efficacy (21%+ CR/CRh rate) and a favorable safety profile with minimal drug interactions.

• Clinician and pharmacist feedback has been positive, citing differentiation in efficacy, safety, compatibility, and dosing simplicity.

• Early payer feedback recognizes Komzifti's differentiation among menin inhibitors.

• $2.1 million in revenue has been pre-announced; further launch metrics and payer data to be shared in upcoming earnings.

• The relapsed/refractory NPM1-mutant AML market is estimated at $350–400 million TAM, with expectations to build market leadership over time.

Clinical development and trial updates

• The phase III KOMET-017 trial covers both intensive (7+3) and non-intensive (Venetoclax + Azacitidine) regimens, with over 200 sites planned globally and robust site engagement.

• Accelerated approval endpoints target a 10–15% improvement in CR rates over standard of care, aiming for survival benefits.

• The trial design includes post-consolidation maintenance, with the goal of enabling prolonged treatment durations.

• Initial data from KOMET-017 is expected in 2028, with high confidence in meeting this timeline.

• The frontline AML market opportunity is estimated at $7 billion, with a 55/45 split between intensive and non-intensive patients.